title: Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease.
abstract: OBJECTIVE
  This was a Phase 2 study (NCT02015793) to evaluate the pharmacokinetics, safety, and efficacy of adalimumab in Chinese patients with Crohn's disease (CD).
  
  
  METHODS
  Thirty, adult Chinese patients with CD (CD Activity Index [CDAI] 220-450; high-sensitivity [hs]-C-reactive protein [CRP] ≥3 mg/L) received double-blind adalimumab 160/80 mg or 80/40 mg at weeks 0/2, followed by 40 mg at weeks 4 and 6. An open-label extension period occurred from weeks 8-26; patients received 40 mg adalimumab every other week. Serum adalimumab concentration and change from baseline in fecal calprotectin (FC) were measured during the double-blind period. Clinical remission (CDAI <150), response (decrease in CDAI ≥70 points from baseline), and change from baseline in hs-CRP were assessed through week 26. Nonresponder imputation was used for missing categorical data and last observation carried forward for missing hs-CRP/FC values. No formal hypothesis was tested. Adverse events were monitored.
  
  
  RESULTS
  Mean adalimumab serum concentrations during the induction phase were 13.9-18.1 µg/mL (160/80 mg group) and 7.5-9.5 µg/mL (80/40 mg group). During the double-blind period, higher remission/response rates and greater reductions from baseline in hs-CRP and FC were observed with adalimumab 160/80 mg compared to that with 80/40 mg. Adverse event rates were similar among all treatment groups.
  
  
  CONCLUSIONS
  Adalimumab serum concentrations in Chinese patients with CD were comparable to those observed previously in Western and Japanese patients. Clinically meaningful remission rates and improvement in inflammatory markers were achieved with both dosing regimens; changes occurred rapidly with adalimumab 160/80 mg induction therapy. No new safety signals were reported.
authors.affiliation: Xijing Hospital of the Fourth Military Medical University, Xi'an, China.
authors.forename: Kai-Chun
authors.initials: KC
authors.lastname: Wu
authors.affiliation: Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
authors.forename: Zhi Hua
authors.initials: ZH
authors.lastname: Ran
authors.affiliation: The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
authors.forename: Xiang
authors.initials: X
authors.lastname: Gao
authors.affiliation: The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
authors.forename: Minhu
authors.initials: M
authors.lastname: Chen
authors.affiliation: Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Zhong
authors.affiliation: The Military General Hospital of Beijing, PLA, Beijing, China.
authors.forename: Jian-Qiu
authors.initials: JQ
authors.lastname: Sheng
authors.affiliation: St. Vincent's Hospital and University of Melbourne, Melbourne, Australia.; Imperial College, London, UK.
authors.forename: Michael A
authors.initials: MA
authors.lastname: Kamm
authors.affiliation: Translational Gastroenterology Unit, Oxford, UK.
authors.forename: Simon
authors.initials: S
authors.lastname: Travis
authors.affiliation: AbbVie, North Chicago, Illinois, USA.
authors.forename: Kori
authors.initials: K
authors.lastname: Wallace
authors.affiliation: AbbVie, North Chicago, Illinois, USA.
authors.forename: Nael M
authors.initials: NM
authors.lastname: Mostafa
authors.affiliation: AbbVie, North Chicago, Illinois, USA.
authors.forename: Marisa
authors.initials: M
authors.lastname: Shapiro
authors.affiliation: AbbVie, North Chicago, Illinois, USA.
authors.forename: Yao
authors.initials: Y
authors.lastname: Li
authors.affiliation: AbbVie, North Chicago, Illinois, USA.
authors.forename: Roopal B
authors.initials: RB
authors.lastname: Thakkar
authors.affiliation: AbbVie, North Chicago, Illinois, USA.
authors.forename: Anne M
authors.initials: AM
authors.lastname: Robinson
keywords: Adalimumab; Anti-tumor necrosis factor; Crohn disease